20:41 , Sep 8, 2017 |  BC Week In Review  |  Clinical News

FDA approves Tracleer for pediatric PAH

FDA approved a 32 mg tablet of Tracleer bosentan to treat pulmonary arterial hypertension in children ages 3 and older. Johnson & Johnson (NYSE:JNJ) gained Tracleer in its June acquisition of Actelion Ltd. Actelion said Tracleer...
23:20 , Sep 6, 2017 |  BC Extra  |  Company News

FDA approves Tracleer for pediatric PAH

FDA approved a 32 mg tablet of Tracleer bosentan to treat pulmonary arterial hypertension in children ages three and older. Johnson & Johnson (NYSE:JNJ) gained Tracleer in its June acquisition of Actelion Ltd. Actelion said Tracleer...
07:00 , Mar 17, 2016 |  BC Innovations  |  Tools & Techniques

Gut re-action

A group of New York academics has developed a protocol to turn human pluripotent stem cells into gut neurons, and believes it could provide the first non-surgical treatment for Hirschsprung's disease - a rare disorder...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Clinical News

Tracleer bosentan: Phase IV data

The double-blind, international Phase IV COMPASS-2 trial in about 334 patients with symptomatic PAH who were receiving sildenafil for >=12 weeks prior to randomization showed that add-on treatment with oral Tracleer missed the primary endpoint...
07:00 , Sep 6, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Endothelin B receptor Mouse studies suggest antagonizing endothelin B receptor could help prevent or treat melanoma...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Clinical News

SPI-1620: Phase I data

Top-line data from Part 1 of a 2-part, open-label, dose-escalation, U.S. Phase I trial in 30 patients who have failed all standard therapy showed that IV SPI-1620 on days 1, 8, and 15 plus docetaxel...
07:00 , Oct 11, 2010 |  BioCentury  |  Product Development

Staying on the A Train

Based on preclinical data implicating the endothelin A pathway in a variety of pro-oncogenic roles, AstraZeneca plc has been developing its zibotentan specific endothelin A receptor antagonist to treat prostate cancer. While it's still unclear...
08:00 , Mar 8, 2010 |  BC Week In Review  |  Clinical News

Tracleer bosentan: Preliminary Phase III data

Preliminary data from the double-blind, international Phase III BUILD-3 trial in 616 patients showed that 125 mg twice-daily Tracleer missed the primary endpoint of significantly reducing time to occurrence of disease worsening or death vs....
07:00 , May 18, 2009 |  BC Week In Review  |  Clinical News

Tracleer bosentan: Phase III ongoing

Actelion said an independent DSMB recommended continuation of the double-blind, placebo-controlled, international Phase III BUILD-3 trial evaluating 125 mg of Tracleer given twice daily in 616 patients based on an interim efficacy and futility analysis...
07:00 , Jul 28, 2008 |  BC Week In Review  |  Clinical News

Tracleer bosentan: Phase III expanded

Actelion expanded enrollment in the double-blind, placebo-controlled, international, Phase III BUILD-3 trial to around 600 patients. The company said the original target enrollment of 390 patients had been achieved in 1Q08, and the study had...